NEO-216

N/A

Report date: 2026/01/27 17:57:35
NME

Base Information

Drug NameNEO-216
Drug Alias Name3 bromopyvate POHBromopyruvate POH
ClassificationSmall molecules
Mechanisms of ActionAlkylating agentsApoptosis stimulantsMannan-binding lectin serine protease 2 inhibitors +[5] 
TargetsGTPase RasPyruvate dehydrogenase complexMannan-binding lectin serine protease 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNeonc Technologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNeonc Technologies Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A